KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBT (2016 - 2025)

Historic EBT for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$100.8 million.

  • Halozyme Therapeutics' EBT fell 15658.87% to -$100.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $466.9 million, marking a year-over-year decrease of 1620.03%. This contributed to the annual value of $466.9 million for FY2025, which is 1620.03% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' EBT stood at -$100.8 million, which was down 15658.87% from $219.0 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' EBT peaked at $219.0 million during Q3 2025, and registered a low of -$100.8 million during Q4 2025.
  • For the 5-year period, Halozyme Therapeutics' EBT averaged around $93.5 million, with its median value being $92.3 million (2021).
  • As far as peak fluctuations go, Halozyme Therapeutics' EBT soared by 56103.09% in 2021, and later plummeted by 15658.87% in 2025.
  • Over the past 5 years, Halozyme Therapeutics' EBT (Quarter) stood at $54.8 million in 2021, then increased by 29.16% to $70.8 million in 2022, then surged by 42.92% to $101.2 million in 2023, then skyrocketed by 76.14% to $178.2 million in 2024, then plummeted by 156.59% to -$100.8 million in 2025.
  • Its EBT stands at -$100.8 million for Q4 2025, versus $219.0 million for Q3 2025 and $204.9 million for Q2 2025.